The Genomics Core Facility (GCF) provides state-of-the-art high-throughput genomics services and expertise to support research across Norway. GCF is situated at the Department of Clinical and Molecular Medicine (IKOM) and is co-localized with the sequencing laboratory at the Division of Laboratory Medicine at St. Olavs Hospital, enabling close interaction with both research and clinical environments. Through strong integration with NTNU, St. Olav’s Hospital, and the national NorSeq infrastructure, we support a wide range of biomedical and translational research initiatives across Norway.
GCF is also a node in the national research infrastructure NorSeq.

What Are Genomics and Multi-Omics?

Genomics is the study of an organism’s entire set of DNA, including all its genes, to understand how genetic information influences biological functions and disease. Multi-omics takes this a step further by integrating data from multiple molecular layers—such as RNA (transcriptomics), proteins (proteomics), and epigenetic modifications—to provide a comprehensive view of how cells and systems operate.

Together, these approaches allow researchers to move beyond single-gene studies and explore complex interactions that drive health and disease. By combining genomics and multi-omics, scientists can uncover the genetic basis of disorders, identify biomarkers for early diagnosis, map intricate biological pathways, and design personalized treatments tailored to individual patients. This integrated perspective is essential for advancing precision medicine and translating discoveries into improved diagnostics and therapies.

At GCF, we help you integrate genomics and multi-omics approaches into your research projects, ensuring that you gain the most comprehensive insights possible.

Comprehensive Genomics and Multi-Omics Services

GCF offers a broad range of wet-lab genomics services, including DNA and RNA sequencing on Illumina platforms, as well as single-cell, single-nucleus, and spatial transcriptomics using 10x Genomics and Parse Biosciences. The facility also performs large-scale SNP genotyping, DNA methylation microarrays (Illumina), and multiplexed protein profiling through Olink Proteomics-by-Genomics.

High-quality DNA/RNA is required for all analyses, and users are encouraged to follow GCF’s sample preparation guidelines or seek extraction support from BioBank1 at Helse Midt-Norge.

GCF integrates dedicated bioinformatics expertise to support study design, data processing, quality control, statistical analysis, and interpretation, ensuring users receive comprehensive assistance throughout their genomics and multi-omics projects.

Flexible Service Models

GCF is a flexible service provider supporting both local and national projects. We offer:

• Sequencing-only services for users who perform their own library preparation or analysis

• Full end-to-end project workflows, including study design, sample preparation, library construction, sequencing, data processing, and tailored bioinformatic analyses

Our experienced staff ensure high-quality data generation and personalized solutions for projects of all sizes.

For a complete overview of available services and equipment, please visit our Services and Equipment page.

Service Request

For inquiries about services, prices, or project planning, please contact the Genomics Core Facility Head/Manager.

Head/Manager: Vidar Beisvåg, PhD, Tlf: +47 73598469 / +47 92044176

News

• Nowember 2024: In this study by Bednarska et al., published in Microorganisms (2025), they used next-generation sequencing (NGS) of the bacterial 16S rRNA gene to generate metagenomic profiles from stool samples. These profiles were correlated with clinical measures, revealing reduced alpha diversity and distinct beta diversity in participants with high fasting glucose. NGS enabled detailed taxonomic analysis, identifying microbial shifts such as increased P. copri and decreased several phyla, providing insights into potential biomarkers for early type 2 diabetes intervention.

• August 2025: GCF has expanded its proteomics capabilities by introducing Olink® Reveal assays—part of Olink’s “Proteomics by Genomics” approach—providing high-throughput protein biomarker analysis integrated with genomic workflows.

• July 2024:  Using ITS1-targeted NGS, this recent study by Ignacio Catalán-Serra et al. (Inflamm Bowel Dis, 2024) profiled fungal communities in IBD patients and healthy controls, uncovering distinct mycobiome shifts. NGS enabled detection of Candida enrichment in active disease, depletion of Penicillium species, and associations between specific fungi and disease activity, phenotype, and prognosis, including links to complicated Crohn’s disease and surgical need.

Staff at the Genomics Core Facility